Microbot Medical (NASDAQ:MBOT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Microbot Medical (NASDAQ:MBOT - Free Report) from a sell rating to a hold rating in a research report released on Saturday.

Separately, HC Wainwright reiterated a "buy" rating and issued a $9.00 target price on shares of Microbot Medical in a research report on Thursday, April 10th.

Microbot Medical Price Performance

Shares of MBOT stock traded down $0.14 on Friday, hitting $2.34. 1,334,092 shares of the company's stock were exchanged, compared to its average volume of 1,732,463. The stock has a market cap of $85.12 million, a P/E ratio of -2.92 and a beta of 1.14. Microbot Medical has a 12 month low of $0.82 and a 12 month high of $3.38. The company has a 50 day moving average of $2.46 and a 200 day moving average of $1.86.

Microbot Medical (NASDAQ:MBOT - Get Free Report) last posted its earnings results on Wednesday, May 21st. The biotechnology company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.07. Sell-side analysts predict that Microbot Medical will post -0.71 EPS for the current fiscal year.

Hedge Funds Weigh In On Microbot Medical

A number of hedge funds have recently made changes to their positions in MBOT. Geode Capital Management LLC raised its position in shares of Microbot Medical by 7.9% during the fourth quarter. Geode Capital Management LLC now owns 142,659 shares of the biotechnology company's stock worth $160,000 after acquiring an additional 10,442 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Microbot Medical during the fourth quarter worth about $118,000. Virtu Financial LLC bought a new position in shares of Microbot Medical during the first quarter worth about $42,000. Finally, Goldman Sachs Group Inc. bought a new position in shares of Microbot Medical during the first quarter worth about $57,000. 16.30% of the stock is currently owned by institutional investors.

About Microbot Medical

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.